Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

The SUMO Pathway in Hematomalignancies and Their Response to Therapies

Abstract : SUMO (Small Ubiquitin-related MOdifier) is a post-translational modifier of the ubiquitin family controlling the function and fate of thousands of proteins. SUMOylation is deregulated in various hematological malignancies, where it participates in both tumorigenesis and cancer cell response to therapies. This is the case for Acute Promyelocytic Leukemias (APL) where SUMOylation, and subsequent destruction, of the PML-RARα fusion oncoprotein are triggered by arsenic trioxide, which is used as front-line therapy in combination with retinoic acid to cure APL patients. A similar arsenic-induced SUMO-dependent degradation was also documented for Tax, a human T-cell lymphotropic virus type I (HTLV1) viral protein implicated in Adult T-cell Leukemogenesis. SUMOylation also participates in Acute Myeloid Leukemia (AML) response to both chemo-and differentiation therapies, in particular through its ability to regulate gene expression. In Multiple Myeloma, many enzymes of the SUMO pathway are overexpressed and their high expression correlates with lower response to melphalan-based chemotherapies. B-cell lymphomas overexpressing the c-Myc oncogene also overexpress most components of the SUMO pathway and are highly sensitive to SUMOylation inhibition. Targeting the SUMO pathway with recently discovered pharmacological inhibitors, alone or in combination with current therapies, might therefore constitute a powerful strategy to improve the treatment of these cancers.
Type de document :
Article dans une revue
Liste complète des métadonnées

Littérature citée [115 références]  Voir  Masquer  Télécharger
Contributeur : Guillaume Bossis <>
Soumis le : mardi 7 avril 2020 - 14:35:40
Dernière modification le : mercredi 3 juin 2020 - 11:10:04


Fichiers éditeurs autorisés sur une archive ouverte




Mathias Boulanger, Rosa Paolillo, Marc Piechaczyk, Guillaume Bossis. The SUMO Pathway in Hematomalignancies and Their Response to Therapies. International Journal of Molecular Sciences, MDPI, 2019, 20 (16), pp.3895. ⟨10.3390/ijms20163895⟩. ⟨hal-02392498⟩



Consultations de la notice


Téléchargements de fichiers